Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (BEIGF) Income from Continuing Operations (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Income from Continuing Operations for 11 consecutive years, with 66502000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 143.79% to 66502000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 286933000.0 through Dec 2025, up 144.5% year-over-year, with the annual reading at 286933000.0 for FY2025, 144.5% up from the prior year.
  • Income from Continuing Operations for Q4 2025 was 66502000.0 at BeOne Medicines, down from 124841000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 215413000.0 in Q3 2023, with the low at 590678000.0 in Q4 2021.
  • Average Income from Continuing Operations over 5 years is 234300700.0, with a median of 299790500.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations plummeted 754.48% in 2022, then soared 202.88% in 2025.
  • Over 5 years, Income from Continuing Operations stood at 590678000.0 in 2021, then increased by 24.61% to 445335000.0 in 2022, then grew by 17.47% to 367553000.0 in 2023, then soared by 58.68% to 151881000.0 in 2024, then soared by 143.79% to 66502000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 66502000.0, 124841000.0, and 94320000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.